Safety, efficacy, and pharmacokinetics of TBR-652, a CCR5/CCR2 antagonist, in HIV-1-infected, treatment-experienced, CCR5 antagonist-naive subjects

Journal of Acquired Immune Deficiency Syndromes

Volumn 57, Issue 2, 2011, Pages 118-125

  Lalezari, Jacob ^a   Gathe, Joseph ^b   Brinson, Cynthia ^c   Thompson, Melanie ^d   Cohen, Calvin ^e   Dejesus, Edwin ^f   Galindez, Jorge ^g   Ernst, Jerome A ^h   Martin, David E ⁱ   Palleja, Sandra M ⁱ  

^a Quest Clinical Research   (United States)

^b Private Practice   (United States)

^c Central Texas Clinical Research   (United States)

^d AIDS Research Consortium of Atlanta   (United States)

^e Boston Community Research Initiative of New England   (United States)

^f ORLANDO IMMUNOLOGY CENTER   (United States)

^g CIBIC   (Argentina)

^h ACRIA Center on HIV and Aging   (United States)

ⁱ Tobira Therapeutics Inc   (United States)

Author keywords

antiretroviral therapy; CCR2 antagonists and inhibitors; CCR5 antagonists and inhibitors; clinical trial; phase II; receptors; TBR 652

Indexed keywords

C REACTIVE PROTEIN; CENICRIVIROC; HIGH SENSITIVITY C REACTIVE PROTEIN; HYDROCODONE BITARTRATE PLUS PARACETAMOL; IBUPROFEN; INTERLEUKIN 10; MONOCYTE CHEMOTACTIC PROTEIN 1; ONDANSETRON; PARACETAMOL; PLACEBO; UNCLASSIFIED DRUG; VIRUS RNA;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ABDOMINAL TENDERNESS; ADULT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CD4 LYMPHOCYTE COUNT; CONSCIOUSNESS DISORDER; COUGHING; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; FLATULENCE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; GINGIVA PAIN; GLOSSODYNIA; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERHIDROSIS; HYPOPHOSPHATEMIA; INFECTION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; NEUROLOGIC DISEASE; PANCREATITIS; PRIORITY JOURNAL; PSYCHIATRIC DEPARTMENT; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SINUS CONGESTION; SOMNOLENCE; TONGUE SWELLING; VOMITING; XEROSTOMIA;

ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; BIOLOGICAL MARKERS; CD4 LYMPHOCYTE COUNT; DOUBLE-BLIND METHOD; FEMALE; HALF-LIFE; HIV INFECTIONS; HIV-1; HUMANS; IMIDAZOLES; INFLAMMATION; MALE; MIDDLE AGED; RECEPTORS, CCR2; RECEPTORS, CCR5; RNA, VIRAL; YOUNG ADULT;

EID: 79957967437     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318213c2c0     Document Type: Article

References (30)

1. Deshmane SL, Kremiev S, Amini S, et al. Monocyte chemoattractant protein 1 (MCP-1): an overview. J Interferon Cytokine Res. 2009;29: 313-326.
2. Palleja S, Driz R, Wang-Smith L, et al. Pharmacokinetics (PK), safety, and tolerability of single doses of the chemokine C-C receptor 5 (CCR5) antagonist TBR-652 in healthy volunteers. Poster presented at: 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; July 19-22, 2009; Cape Town, South Africa. Poster WEPEB251.
3. Palleja S,Wang-Smith L, Ogden R, et al. TBR-652, a chemokine receptor 5 (CCR5) antagonist, demonstrates good oral bioavailability and desirable pharmacokinetic (PK) and safety profiles in healthy volunteers. Poster presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 12-19, 2009; San Francisco, CA. Poster 925.
4. Martin D, Palleja S, Pheng L, et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of TBR-652, a chemokine receptor 5 (CCR5) antagonist, in HIV-1-infected, antiretroviral (ARV) treatment-experienced, CCR5 antagonist naive patients. Presented at: 17th Conference on Retrovireuses and Opportunistic Infections (CROI); February 16-19, 2010; San Francisco, CA. Poster 598.
5. Palleja S, Cohen C, Gathe J, et al. Safety and efficacy of TBR-652, a chemokine receptor 5 (CCR5) antagonist, in HIV-1-infected, antiretroviral (ARV) treatment-experienced, CCR5 antagonist-na?̈ve patients. Orally presented at: 17th CROI; February 16-19, 2010; San Francisco, CA. Abstract K-111.
6. Fätkenheuer G, Pozniak AL, Johnson MA, et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med. 2005;11:1170-1172. (Pubitemid 43093663)
7. Baba M, Takashima K, Miyake H, et al. TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans. Antimicrob Agents Chemother. 2005;49:4584-4591. (Pubitemid 41552587)
8. Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol. 2008;214:231-241. (Pubitemid 351160160)
9. Kuller LH, Tracy R, Belloso W, et al. for the INSIGHT SMART Study Group. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5:e203.
10. Neuhaus J, Jacobs DR, Baker JV, et al; for the INSIGHT SMART, MESA, and CARDIA Research Groups. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis. 2010;201:1788-1795.
11. Tracy RP. Inflammation and premature aging in HIV+ people. Presented at: 1st International Workshop on HIV and Aging; October 4-5, 2010; Baltimore, MD. Available at: http://regist2.virology-education.com/ 1stAging/docs/29-Tracy.pdf.
12. Onen NF, Overton ET, Seyfried W, et al. Aging and HIV infection: a comparison between older HIV-infected persons and the general population. HIV Clin Trials. 2010;11:100-109.
13. Medina S. Wessman D, Krause D,et al. Coronary aging in HIV-infected patients [letter]. Clin Infect Dis. 2010;51:990-995.
14. Guaraldi G, Zona S, Alexopoulos N, et al. Coronary aging in HIV-infected patients. Clin Infect Dis. 2009;49:1756-1762.
15. Ross AC, Rizk N, O'Riordan MA, et al. Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis. 2009;49:1119-1127.
16. Papadopoulou C, Corrigall V, Taylor R, et al. The role of the chemokines MCP-1, GRO-alpha, IL-8 and their receptors in the adhesion of monocytic cells to human atherosclerotic plaques. Cytokine. 2008;43:181-186.
17. Caron-Debarle M, Boccara F, Lagathu C, et al. Adipose tissue as a target of HIV-1 antiretroviral drugs. Potential consequences on metabolic regulations. Curr Pharm Des. 2010;30:3352-3360.
18. Kamei N, Tobe K, Suzuki R, et al. Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J Biol Chem. 2006;281:26602-26614. (Pubitemid 44401869)
19. Tamura Y, Sugimoto M, Murayama T, et al. C-C chemokine receptor 2 inhibitor improves diet-induced development of insulin resistance and hepatic steatosis in mice. J Atheroscler Thromb. 2010;17:219-228.
20. Campbell GR, Spector SA. CCL2 increases X4-tropic HIV-1 entry into resting CD4+ T cells. J Biol Chem. 2008;283:30745-30753.
21. Berry S, Moore R, Gabo K. Reasons for hospitalizations differ among older and younger HIV-infected persons. Rev Antivir Ther Infect Dis. 2010;9:13. Available at: http://regist2.virology-education.com/1stAging/ docs/23-Berry.pdf.
22. Zhao Q. Dual targeting of CCR2 and CCR5: therapeutic potential for immunologic and cardiovascular diseases. J Leuk Biol. 2010;88:41-55.
23. Serbina NV, Jia T, Hohl TM, et al. Monocyte-mediated defense against microbial pathogens. Annu Rev Immunol. 2008;26:421-452. (Pubitemid 351600381)
24. Vivithanaporn P, Heo G, Gamble J, et al. Neurologic disease burden in treated HIV/AIDS predicts survival: a population-based study. Neurology. 2010;75:1150-1158.
25. Sozzani S, Introna M, Bernasconi et al. MCP-1 and CCR2 in HIV infection: regulation of antagonist and receptor expression. J Leukoc Biol. 1997; 62:30-33. (Pubitemid 27321736)
26. Fumaz CR, Ferrer MJ, Muñoz-Moreno JA, et al. Gender differences in aging associated symptoms and their impact on quality of life in HIVinfected subjects. Rev Antivir Ther Infect Dis. 2010;9:15. Available at: http://regist2.virology-education.com/1stAging/docs/24-negredo.pdf.
27. Wojna V, De La Torre T, Mayo R, et al. Increased depression and neurocognitive dysfunction in aging HIV-seropositive women despite high CD4 cell counts. Rev Antivir Ther Infect Dis. 2010;9:25.
28. Sok P, Sean BR, Sandra G, et al. Determinants of health and clinical conditions on health outcomes in older adults with HIV/AIDS: the Ontario Positive Places, Healthy Spaces Study. Rev Antivir Ther Infect Dis. 2010;9:33.
29. Demarest J, Bonny T, Vavro C, et al. HIV-1 Co-receptor Tropism in Treatment-Naive and Experienced Subjects. In: Proceedings of the 44th ICAAC, Washington, DC, Oct 30 to Nov 2, 2004 p. 300.
30. Shepherd JC, Jacobson LP, Qiao W, et al. Emergence and persistence of CXCR4-tropic HIV-1 in a population of men from the Multicenter AIDS Cohort Study. J Infect Dis. 2008;198:1104-1112.